HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- Status
- RECRUITING
- Phase
- PHASE4
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
- Status
- COMPLETED
- Phase
- PHASE1
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CURATE.AI Optimized Modulation for Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
- Status
- COMPLETED
- Phase
- NA
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
- Status
- UNKNOWN
- Phase
- PHASE2
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Status
- RECRUITING
- Phase
- PHASE3
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1